...
首页> 外文期刊>Clinical neuropharmacology >Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
【24h】

Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

机译:具有前提叶碱的risperidone组合治疗用于治疗自闭症谱系疾病的烦躁:随机,双盲,安慰剂控制的临床试验

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives Propentofylline is a xanthine phosphodiesterase inhibitor and adenosine reuptake blocker with neuroprotective effects linked to anti-inflammatory and antiexcitatory properties. This is a double-blind, placebo-controlled trial investigating the potential beneficial effects of propentofylline, as an adjunctive treatment with risperidone, on the severity and behavioral abnormalities of autism spectrum disorder (ASD). Methods A total of 48 children with ASD were randomly allocated into 2 groups of risperidone (initiating at 0.5 mg/d) plus propentofylline (initiating at 300 mg/d) and risperidone plus placebo. The Aberrant Behavior Checklist-Community (ABC-C) and Childhood Autism Rating Scale (CARS) were used for the evaluation of ASD severity and behavioral disruptions at baseline, week 4, and week 10. Primary outcome measure of the study was ABC-C irritability subscale score, whereas CARS score along with other 4 subscales of ABC-C (lethargy/social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech subscales) were considered as secondary outcome measures. Results Results from the general linear model repeated measures analysis demonstrated significant time-treatment interaction on irritability subscale (F-1.55 = 3.45; P = 0.048) and CARS (F-1.41 = 4.08; P = 0.034) scores. Compared with the placebo group, children receiving propentofylline showed greater improvements in the CARS score (P = 0.037) from baseline to the study endpoint. Our results found no significant time-treatment effect on other subscales of ABC-C. Two trial groups were comparable based on the frequency of adverse effects. Conclusions Our findings demonstrated that adjunctive treatment with propentofylline is effective in alleviating disease severity and improving irritability in ASD patients. However, larger studies with longer durations are required to confirm these results.
机译:特征异常的目标是黄嘌呤磷酸二酯酶抑制剂和腺苷再摄取阻滞剂,与抗炎和抗肿瘤性能相关的神经保护作用。这是一种双盲,安慰剂对照试验,调查前提植物的潜在有益效果,作为丙酮酮的辅助治疗,对自闭症谱系障碍(ASD)的严重程度和行为异常。方法将共分配了48例ASD的儿童,分配成2组Risperidone(在0.5mg / d时启动)加上前戊烯碱(在300mg / d)和risperidone加安慰剂。异常行为核对表 - 社区(ABC-C)和童年自闭症评级规模(汽车)用于评估基线,第4周和第10周的ASD严重程度和行为中断。研究的主要结果衡量是ABC-C令人烦躁的分量分数,而汽车得分随着其他4位ABC-C(嗜睡/社会戒断,陈规定型行为,多动症/不惯用,以及不恰当的语音分量)被视为二次结果措施。结果由一般线性模型的重复测量分析结果表明了对烦躁子级的显着的时间处理相互作用(F-1.55 = 3.45; P = 0.048)和汽车(F-1.41 = 4.08; P = 0.034)分数。与安慰剂集团相比,接受Pharentofylline的儿童从基线到研究终点的基准显示出更大的改进。我们的结果发现对ABC-C的其他类别没有显着的时间治疗效果。基于不良反应的频率,两组试验组可相当。结论我们的研究结果表明,具有前提叶碱的辅助治疗可有效缓解疾病严重程度,提高ASD患者的烦躁。然而,需要更大的持续时间的研究来确认这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号